IMAGE: Insilico Medicine collaborates with MAWI to develop a range of multi-modal biomarkers of aging and mortality to help prevent the onset of cardiovascular diseases and extend human longevity view more
Credit: Insilico Medicine
Friday, September 28th, 2018, Rockville, MD. Cardiovascular disease is the leading cause of death and disability in the world. On the eve of the annual World Heart Day, September 29th, Insilico Medicine, Inc., a Rockville-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research announced a research collaboration agreement with MAWI, the next-generation consumer and clinical wearable company, the developer of one of the most accurate clinical-grade ECG wearable devices. The aim of the collaboration is to develop a range of multi-modal biomarkers of aging and mortality to help prevent the onset of cardiovascular diseases and extend human longevity.
“We believe that the revolution in the accurate ECG sensors will start with MAWI which will complement any smart watch solution with a range of specific applications geared towards extending longevity and healthspan of the individual. At MAWI we value great science and research-backed applications and a partnership with Insilico Medicine will help us deliver new
Article originally posted at